Use of inotropic agents in treatment of systolic heart failure

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 29060-29068

  Tariq, Sohaib ^a   Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Digoxin; Dobutamine; Dopamine; Inotropes; Levosimendan; Milrinone; Norepinephrine; Omecamtiv mecarbil

Indexed keywords

CARVEDILOL; DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; NESIRITIDE; NORADRENALIN; OMECAMTIV MECARBIL; CARDIOTONIC AGENT;

ASSISTED CIRCULATION; CARDIOGENIC SHOCK; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EOSINOPHILIA; EXTRACORPOREAL OXYGENATION; HEART ATRIUM ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INOTROPISM; INTRAAORTIC BALLOON PUMP; LEFT VENTRICULAR ASSIST DEVICE; LONG TERM CARE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MYOCARDITIS; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; DRUG EFFECTS; HEART; HEART FAILURE, SYSTOLIC; PATHOPHYSIOLOGY; SYSTOLE;

CARDIOTONIC AGENTS; HEART; HEART FAILURE, SYSTOLIC; HUMANS; SYSTOLE;

EID: 84949464178     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226147     Document Type: Review

References (43)

1. Packer, M.; Gheorghiade, M.; Young, J.B.; Costantini, P.J.; Adams, K.F.; Cody, R.J.; Smith, L.K.; van Voorhees, L.; Gourley, L.A.; Jolly, M.K. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors: RADIANCE Study. N. Engl. J. Med. 1993, 329, 1-7.
2. Wang, X.C.; Zhu, D.M.; Shan, Y.X. Dobutamine therapy is associated with worse clinical outcomes compared with nesiritide therapy for acute decompensated heart failure: A systematic review and meta-analysis. Am. J. Cardiovasc. Drugs 2015, 15, 429-437.
3. De Backer, D.; Biston, P.; Devriendt, J.; Madl, C.; Chochrad, D.; Aldecoa, C.; Brasseur, A.; Defrance, P.; Gottignies, P.; Vincent, J.L. et al. Comparison of dopamine and norepinephrine in the treatment of shock. N. Engl. J. Med. 2010, 362, 779-789.
4. Cuffe, M.S.; Califf, R.M.; Adams, K.F., Jr; Benza, R.; Bourge, R.; Colucci, W.S.; Massie, B.M.; O’Connor, C.M.; Pina, I.; Quigg, R. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 2002, 287, 1541-1547.
5. Mebazaa, A.; Nieminen, M.S.; Packer, M.; Cohen-Solal, A.; Kleber, F.X.; Pocock, S.J.; Thakkar, R.; Padley, R.J.; Põder, P.; Kivikko, M. et al. Levosimendan vs. dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 2007, 297, 1883-1891.
6. Packer, M.; Colucci, W.; Fisher, L.; Massie, B.M.; Teerlink, J.R.; Young, J.; Padley, R.J.; Thakkar, R.; Delgado-Herrera, L.; Salon, J. et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J. Am. Coll. Cardiol. Heart Fail. 2013, 1, 103-111.
7. Cleland, J.G.; Teerlink, J.R.; Senior, R.; Nifontov, E.M.; Mc Murray, J.J.; Lang, C.C.; Tsyrlin, V.A.; Greenberg, B.H.; Mayet, J.; Francis, D.P. et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011, 378, 676-683.
8. Teerlink, J.R.; Clarke, C.P.; Saikali, K.G.; Lee, J.H.; Chen, M.M.; Escandon, R.D.; Elliott, L.; Bee, R.; Habibzadeh, M.R.; Goldman, J.H. et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: A first-in-man study. Lancet 2011, 378, 667-675.
9. Gheorghiade, M.; St Clair, J.; St Clair, C.; Beller, G.A. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J. Am. Coll. Cardiol. 1987, 9, 849-857.
10. Gheorghiade, M.; Braunwald, E. Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 2009, 302, 2146-2147.
11. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 1997, 336, 525-533.
12. Rathore, S.S.; Curtis, J.P.; Wang, Y.; Bristow, M.R.; Krumholz, H.M. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003, 289, 871-878.
13. Rathore, S.S.; Wang, Y.; Krumholz, H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J. Med. 2002, 347, 1403-1411.
14. Adams, K.F., Jr; Patterson, J.H.; Gattis, W.A.; O’Connor, C.M.; Lee, C.R.; Schwartz, T.A.; Gheorghiade, M. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: A retrospective analysis. J. Am. Coll. Cardiol. 2005, 46, 497-504.
15. Ahmed, A.; Aronow, W.S.; Fleg, J.L. Predictors of mortality and hospitalization in women with heart failure in the Digitalis Investigation Group trial. Am. J. Ther. 2006, 13, 325-331.
16. Ahmed, A.; Aban, I.B.; Weaver, M.T.; Aronow, W.S.; Fleg, J.L. Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction. Eur. J. Heart Fail. 2006, 8, 409-419.
17. Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.L. et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013, 62, E147-E239.
18. McMurray, J.J.; Adamopoulos, S.; Anker, S.D.; Auricchio, A.; Böhm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C.; Gomez-Sanchez, M.A. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2012, 14, 803-869.
19. Goldstein, R.E.; Boccuzzi, S.J.; Cruess, D.; Nattel, S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991, 83, 52-60.
20. Aronow, W.S. Management of atrial fibrillation in the elderly. Minerva Med. 2009, 100, 3-24.
21. Naqvi, S.; Ahmed, I.; Siddiqi, R.; Hussain, S.A. Digoxin as a rescue drug in intra aortic balloon pump and inotrope dependent patients. J. Ayub. Med. Coll. Abbottabad 2010, 22, 8-12.
22. Bellomo, R.; Chapman, M.; Finfer, S.; Hickling, K.; Myburgh, J. Low dose dopamine in patients with early renal dysfunction: A placebo controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000, 356, 2139-2143.
23. Chen, H.H.; Anstrom, K.J.; Givertz, M.M.; Stevenson, L.W.; Semigran, M.J.; Goldsmith, S.R.; Bart, B.A.; Bull, D.A.; Stehlik, J.; LeWinter, M.M. et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial. JAMA 2013, 310, 2533-2543.
24. Metra, M.; Nodari, S.; D’Aloia, A.; Muneretto, C.; Robertson, A.D.; Bristow, M.R.; Dei Cas, L. β-Blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J. Am. Coll. Cardiol. 2002, 40, 1248-1258.
25. Takkenberg, J.J.; Czer, L.S.; Fishbein, M.C.; Luthringer, D.J.; Quartel, A.W.; Mirocha, J. Eosinophilic myocarditis in patients awaiting heart transplantation. Crit. Care Med. 2004, 32, 714-721.
26. Oliva, F.; Latini, R.; Politi, A.; Staszewsky, L.; Maggioni, A.P.; Nicolis, E.; Mauri, F. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am. Heart J. 1999, 138, 247-253.
27. Jolly, S.; Newton, G.; Horlick, E.; Seidelin, P.H.; Ross, H.J.; Husain, M.; Dzavik, V. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am. J. Cardiol. 2005, 96, 1617-1620.
28. Overgaard, C.B.; Dzavik, V. Inotropes and vasopressors: Review of physiology and clinical use in cardiovascular disease. Circulation 2008, 118, 1047-1056.
29. Colucci, W.S.; Wright, R.F.; Jaski, B.E.; Fifer, M.A.; Braunwald, E. Milrinone and dobutamine in severe heart failure: Differing hemodynamic effects and individual patient responsiveness. Circulation 1986, 73, III175-III183.
30. Cox, Z.L.; Calcutt, M.W.; Morrison, T.B.; Akers, W.S.; Davis, M.B.; Lenihan, D.J. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction. J. Cardiovasc. Pharmacol. Ther. 2013, 18, 433-438.
31. Marius-Nunez, A.L.; Heaney, L.; Fernandez, R.N.; Clark, W.A.; Ranganini, A.; Silber, E.; Denes, P. Intermittent inotropic therapy in an outpatient setting: A cost-effective therapeutic modality in patients with refractory heart failure. Am. Heart J. 1996, 132, 805-808.
32. Felker, G.M.; Benza, R.L.; Chandler, A.B.; Leimberger, J.D.; Cuffe, M.S.; Califf, R.M.; Gheorghiade, M.; O’Connor, C.M.; OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: Results from the OPTIME-CHF study. J. Am. Coll. Cardiol. 2003, 41, 997-1003.
33. Abraham, W.T.; Adams, K.F.; Fonarow, G.C.; Costanzo, M.R.; Berkowitz, R.L.; LeJemtel, T.H.; Cheng, M.L.; Wynne, J.; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol. 2005, 46, 57-64.
34. Packer, M.; Carver, J.R.; Rodeheffer, R.J.; Ivanhoe, R.J.; DiBianco, R.; Zeldis, S.M.; Hendrix, G.H.; Bommer, W.J.; Elkayam, U.; Kukin, M.L. et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 1991, 325, 1468-1475.
35. Amsallem, E.; Kasparian, C.; Haddour, G.; Boissel, J.P.; Nony, P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst. Rev. 2005, 1, doi:10.1002/14651858.CD002230.pub2.
36. Dec, G.W. Acute decompensated heart failure: The shrinking role of inotropic therapy. J. Am. Coll. Cardiol. 2005, 46, 65-67.
37. Nieminen, M.S.; Akkila, J.; Hasenfuss, G.; Kleber, F.X.; Lehtonen, L.A.; Mitrovic, V.; Nyquist, O.; Remme, W.J. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J. Am. Coll. Cardiol. 2000, 36, 1903-1912.
38. Slawsky, M.T.; Colucci, W.S.; Gottlieb, S.S.; Greenberg, B.H.; Haeusslein, E.; Hare, J.; Hutchins, S.; Leier, C.V.; LeJemtel, T.H.; Loh, E. et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000, 102, 2222-2227.
39. Follath, F.; Cleland, J.G.; Just, H.; Papp, J.G.; Scholz, H.; Peuhkurinen, K.; Harjola, V.P.; Mitrovic, V.; Abdalla, M.; Sandell, E.P. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002, 360, 196-202.
40. Moiseyev, V.S.; Põder, P.; Andrejevs, N.; Ruda, M.Y.; Golikov, A.P.; Lazebnik, L.B.; Kobalava, Z.D.; Lehtonen, L.A.; Laine, T.; Nieminen, M.S. et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart J. 2002, 23, 1422-1432.
41. Teerlink, J.R. A novel approach to improve cardiac performance: Cardiac myosin activators. Heart Fail. Rev. 2009, 14, 289-298.
42. Brozena, S.C.; Twomey, C.; Goldberg, L.R.; Desai, S.S.; Drachman, B.; Kao, A.; Popjes, E.; Zimmer, R.; Jessup, M. A prospective study of continuous intravenous milrinone therapy for status IB patients awaiting heart transplant at home. J. Heart Lung Transplant. 2004, 23, 1082-1086.
43. López-candales, A.L.; Carron, C.; Schwartz, J. Need for hospice and palliative care services in patients with end-stage heart failure treated with intermittent infusion of inotropes. Clin. Cardiol. 2004, 27, 23-28.